Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia in rats

Experimental Physiology

Volumn 92, Issue 2, 2007, Pages 409-416

  Chen, Li Mien ^a,b   Kuo, Wei Wen ^c   Yang, Jaw Ji ^d   Wang, Shyi Gang P ^e   Yeh, Yu Lan ^f   Tsai, Fuu Jen ^g   Ho, Ying Jui ^d   Chang, Mu Hsin ^b   Huang, Chih Yang ^c   Lee, Shin Da ^c  

^a CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b TAICHUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE 5; MITOGEN ACTIVATED PROTEIN KINASE P38; SOMATOMEDIN B; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUSTRALIA; CONTROLLED STUDY; EXCISION; HEART HYPERTROPHY; HEART INDEX; HEART WEIGHT; HISTOLOGY; HYPOXIA; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

EID: 33847766236     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2006.036590     Document Type: Article

References (28)

1. Bazzoni F & Beutler B (1996). The tumor necrosis factor ligand and receptor families. N Engl J Med 334, 1717-1725.
2. Cameron SJ, Itoh S, Baines CP, Zhang C, Ohta S, CheW, Glassman M, Lee JD, Yan C, Yang J & Abe J (2004). Activation of big MAP kinase 1 (BMK1/ERK5) inhibits cardiac injury after myocardial ischemia and reperfusion. FEBS Lett 566, 255-260.
3. Dorn GW 2nd & Hahn HS (2004). Genetic factors in cardiac hypertrophy. Ann N Y Acad Sci 1015, 225-237.
4. Hirano T (1998). Interleukin 6 and its receptor: ten years later. Int Rev Immunol 16, 249-284.
5. Hirota H, Yoshida K, Kishimoto T & Taga T (1995). Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A 92, 4862-4866.
6. Huang CY, Hao LY & Buetow DE (2002a). Insulin-like growth factor-induced hypertrophy of cultured adult rat cardiomyocytes is L-type calcium-channel-dependent. Mol Cell Biochem 231, 51-59.
7. Huang CY, Hao LY & Buetow DE (2002b). Insulin-like growth factor-II induces hypertrophy of adult cardiomyocytes via two alternative pathways. Cell Biol Int 26, 737-739.
8. Huang CY, Hao LY & Buetow DE (2002c). Hypertrophy of cultured adult rat ventricular cardiomyocytes induced by antibodies against the insulin-like growth factor (IGF)-I or the IGF-I receptor is IGF-II-dependent. Mol Cell Biochem 233, 65-72.
9. Kanda T & Takahashi T (2004). Interleukin-6 and cardiovascular diseases. Jpn Heart J 45, 183-193.
10. Kaneko K, Kanda T, Yokoyama T, Nakazato Y, Iwasaki T, Kobayashi I & Nagai R (1997). Expression of interleukin-6 in the ventricles and coronary arteries of patients with myocardial infarction. Res Commun Mol Pathol Pharmacol 97, 3-12.
11. Kodama H, Fukuda K, Pan J, Makino S, Baba A, Hori S & Ogawa S (1997). Leukemia inhibitory factor, a potent cardiac hypertrophic cytokine, activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 81, 656-663.
12. Kopelman PG, Apps MC, Cope T, Ingram DA, Empey DW& Evans SJ (1986). Nocturnal hypoxia and sleep apnoea in asymptomatic obese men. Int J Obesity 10, 211-217.
13. Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K & Kishimoto T (1998). Activation of gp130 transduces hypertrophic signals via STAT3 in cardiac myocytes. Circulation 98, 346-352.
14. Lee SD, Chen LM, Kuo WW, ShuWT, Kuo WH, Huang EJ, Tsai CC, Li PC, Liu JY, Chen TH & Huang CY (2006a). Serum insulin-like growth factor-axis and matrix metalloproteinases in patients with rheumatic arthritis or rheumatic heart disease. Clin Chim Acta 367, 62-68.
15. Lee SD, Chu CH, Huang EJ, Lu MC, Liu JY, Liu CJ, Hsu HH, Lin JA, KuoWW& Huang CY (2006b). Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am J Physiol Endocrinol Metab 291, E306-E314.
16. Lee SD, Huang CY, ShuWT, Chen TH, Lin JA, Hsu HH, Lin CS, Liu CJ, KuoWW& Chen LM (2006c). Pro-inflammatory states and IGF-I level in ischemic heart disease with low or high serum iron. Clin Chim Acta 370, 50-56.
17. Lee SD, Kuo WW, Lin JA, Chu YF,Wang CK, Yeh YL,Wang SG, Liu JY, Chang MH & Huang CY (2007). Effects of long-term intermittent hypoxia on mitochondrial and Fas death receptor dependent apoptotic pathways in rat hearts. Int J Cardiol DOI: 10.1016/j.ijcard.2006.03.064
18. Lee SD, Kuo WW,Wu CH, Lin YM, Lin JA, Lu MC, Yang AL, Liu JY,Wang SG, Liu CJ, Chen LM & Huang CY (2006e). Effects of short- and long-term hypobaric hypoxia on Bcl2 family in rat heart. Int J Cardiol 108, 376-384.
19. Mandi Y, Hogye M, Talha EM, Skolak E & Csanady M (2000). Cytokine production and antibodies against heat shock protein 60 in cardiomyopathies of different origins. Pathobiology 68, 150-158.
20. Neyses L & Pelzer T (1995). The biological cascade leading to cardiac hypertrophy. Eur Heart J 16 (Suppl. N), 8-11.
21. Ng DC, Court NW, dos Remedios CG & Bogoyevitch MA (2003). Activation of signal transducer and activator of transcription (STAT) pathways in failing human hearts. Cardiovasc Res 57, 333-346.
22. Nicol RL, FreyN, Pearson G, CobbM, Richardson J & Olson EN (2001). Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J 20, 2757-2767.
23. Ogata A, Nishimoto N & Yoshizaki K (1999). Advances in interleukin-6 therapy [in Japanese]. Rinsho Byori 47, 321-326.
24. Ohtake S, Nakamura R, Igarashi K, Kuronuma T, Koide N, Akimoto Y & Kubota H (1990). Nocturnal hypoxia and treatment in the patients with Duchenne muscular dystrophy [in Japanese]. Kokyu To Junkan 38, 463-469.
25. Ostadal B, Urbanova D, Ressl J, Prochazka J, Pelouch V & Widimsky J (1981). Changes of the right and left ventricles in rats exposed to intermittent high altitude hypoxia. Cor Vasa 23, 111-120.
26. Rossi MA & Carillo SV (1991). Cardiac hypertrophy due to pressure and volume overload: distinctly different biological phenomena? Int J Cardiol 31, 133-141.
27. Sack M (2002). Tumor necrosis factor-α in cardiovascular biology and the potential role for anti-tumor necrosis factor-α therapy in heart disease. Pharmacol Ther 94, 123-135.
28. Yokoyama T, Nakano M, Bednarczyk JL, McIntyre BW, Entman M & Mann DL (1997). Tumor necrosis factor-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 95, 1247-1252.